Blood sugar levels of older adults with type 1 diabetes are in the hypoglycemic range for more than an hour a day, and blood sugar levels of those with impaired hypoglycemia awareness may be in hypoglycemic range even longer.
The FDA issued a Complete Response Letter rejecting the New Drug Application (NDA) for Zynquista (sotagliflozin; Sanofi and Lexicon) for the treatment of adults with type 1 diabetes, in combination with insulin.
A 50% to 80% basal rate reduction performed 90 minutes before beginning exercise will improve open-loop glucose control and decrease the risk for hypoglycemia during exercise in individuals with type 1 diabetes.
Most patients with type 1 diabetes will experience clinically meaningful differences in glucose level results when comparing laboratory-measured HbA1c levels with HbA1c levels derived from a glucose management indicator.
An improved genetic risk score for type 1 diabetes signiﬁcantly improved identification of persons with type 1 diabetes from those with type 2 diabetes and was useful in identifying adult incident diabetes in newborn screening.